《大行報告》花旗下調微博(WB.US)目標價至18美元 評級「買入」
花旗發表報告指,微博(WB.US)次季總收入按年跌2%至4.4億美元,符合市場預期,惟低於該行預期;經調整純利按年升15%至1.26億美元,符合該行預期,但勝市場預期。管理層指,在宏觀疲弱下7月份增長較6月稍微放緩,而8月份呈現反彈,管理層並對下半年復甦步伐持樂觀看法。
該行降微博今年至2025年各年收入預測分別7.9%、8.4%及9.1%,並降期內非通用會計準則淨利潤預測分別9.1%、10.2%及9%。該行將其美股目標價由20美元下調至18美元,因估值不高,維持其評級為「買入」。
花旗料微博今年全年收入按年跌4%至17.6億美元,經調整純利料5.01億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.